Market Research Report
Zika virus Infections - Pipeline Review, H1 2017
|Published by||Global Markets Direct||Product code||410983|
|Published||Content info||177 Pages
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Zika virus Infections - Pipeline Review, H1 2017, provides an overview of the Zika virus Infections (Infectious Disease) pipeline landscape.
Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Zika virus is a member of the Flaviviridae family. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Zika virus Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Zika virus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Zika virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Zika virus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 32 and 26 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 6 and 5 molecules, respectively.
Zika virus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.